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were used to calculate outcomes. The median age was 6.5 years,
median cell dose infused was 4.1  107/kg and the median
follow time was 22 months (3-96). The cord blood was HLA
identical (6/6) in 12% of the cases, 5/6 in 46%, 4/6 in 39% and
3/6 in 3%. Overall 2 year-LFS was 36  3%. In a multivariate
analysis, only CR1 or CR2 were associated with better LFS (HR
 1.8; P  0.0001). Therefore a separate analysis was performed
according to the disease status. Disease and patient character-
istics and outcomes are listed in the table. All children received
myeloablative conditioning regimen and the majority (67%) re-
ceived CsAcorticoids as GVHD prophylaxis.
In conclusion, these results conﬁrm that UCBT should be pro-
posed as alternative source of allogeneic transplantation for chil-
dren with high risk ALL, in earlier status of the disease, for those
children lacking an HLA identical donor.
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IMPLEMENTING THE STEM CELL THERAPEUTIC AND RESEARCH ACT
OF 2005
Baitty, Robert L., Tims, Shelley E., Wabeke, Anita, Ashton, Robyn,
Gale, Randy, Burdick, James F. Department of Health and Human
Services, Health Resources and Services Administration, Division of
Transplantation, Rockville, MD.
The Stem Cell Therapeutic and Research Act of 2005 was signed
by President Bush on December 20, 2005. Section 2 of the Act
authorizes Federal support for collection of 150,000 new, high
quality cord blood units for a National Cord Blood Inventory,
authorizes a related cord blood demonstration program, and re-
quires that some cord blood units not suitable for clinical trans-
plantation be made available for research. Section 3, among other
things, authorizes the C.W. Bill Young Cell Transplantation Pro-
gram to facilitate unrelated blood stem cell transplants (as the
successor to the National Bone Marrow Donor Registry), calls for
establishment of an Advisory Council to advise the Secretary of the
Department of Health and Human Services (HHS) regarding the
Program and related matters, and requires HHS to recognize one
or more accrediting organizations to accredit cord blood banks
collecting units for the National Cord Blood Inventory. Adminis-
trative responsibility for most provisions of the Act is assigned to
the Health Resources and Services Administration (HRSA) within
the Department of Health and Human Services. This presentation
describes HRSA’s approach to implementing the new programs
authorized by the Act, concentrating on the National Cord Blood
Inventory and the Cord Blood Coordinating Center.
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CULTURE OF CD34 UMBILICAL CORD BLOOD PROGENITORS WITH
NOTCH LIGAND RESULTS IN ENHANCED AND MORE RAPID HUMAN
ENGRAFTMENT IN A PRECLINICAL NOD/SCID MOUSE MODEL
Delaney, Colleen. Clinical Research Division, Fred Hutchinson Cancer
Research Center, Seattle, WA, and Department of Pediatrics, University
of Washington, Seattle, WA.
Our laboratory has developed novel methods for enhancing the
magnitude and kinetics of hematopoietic reconstitution by human
cord blood progenitor cells using the Notch ligand, Delta1. We
have previously shown that culture of CD34CD38 UCB pro-
genitors with Delta1 results in enhanced generation of NOD/
SCID repopulating cells. Furthermore, we have examined effect of
Notch ligand density on induction of endogenous Notch signaling
and subsequent cell-fate of hematopoietic precursors, demonstrat-
ing critical quantitative aspects of Notch signaling in affecting cell
fate outcome.
Based on these ﬁndings, we have developed a clinically feasible
cGMP method for Notch ligand-based expansion of cord blood
precursors. Speciﬁcally, we investigated the use of CD34 versus
CD34CD38 cells as a starting population, optimal cytokines
and medium, selection of culture vessel and culture period for
effects on generation of NOD/SCID repopulating cells. UCB
progenitors were cultured in the presence of a Notch ligand form
consisting of the extracellular domain of Delta1 fused to the Fc
domain of human IgG1 (Delta 1ext-IgG) or control human IgG.
Initial studies demonstrated optimal cytokines consisted of SCF,
FL, TPO, IL6 and IL3, together with ﬁbronectin fragments in
serum free medium. There was no signiﬁcant difference seen in the
CD34 fold expansion with CD34 versus CD34CD38 starting
cells, however, upon transplantation into NOD/SCID mice, there
was a signiﬁcant increase in the level of human engraftment seen
with the CD34 starting cell population (6.93% vs 2%; P  0.01).
Further results from 5 independent experiments in which cord
blood CD34 progenitor cells were cultured for 17 days with
immobilized Delta1extIgG or control resulted in a mean fold expan-
sion of CD34 cells of 230 ( 53) for the Delta cultured cells
versus 65 (31) for the control cultured cells (P  0.03). Delta
cultured cells demonstrated signiﬁcantly enhanced levels of human
engraftment as measured by percent CD45 in the marrow of the
animals at both 3 weeks (Delta1 15.5%, control 2.6%, uncultured
0.2%; P  0.0001) and at 9 weeks (Delta1 29.4%, control 8.9%,
uncultured 7.3%; P  0.0001). We also found signiﬁcantly greater
numbers of SCID repopulating cells (SRC) detected 3 and 9 weeks
following transplantation in the Delta1ext-IgG cultured cells com-
pared to control cultured or non-cultured cells. Relevant to antic-
ipated administration of cultured cord blood units together with a
second non-cultured unit in clinical trials, we determined the
relative contribution to engraftment of co-infused expanded versus
non-manipulated cells in immunodeﬁcient mice, using tissue cul-
ture bags as a closed system. We found increased human engraft-
ment in mice that received co-infusions of cultured and uncultured
cells compared to either unit alone. Moreover, studies demon-
strated that both units contributed to the observed human engraft-
ment suggesting absence of cross-immunologic rejection.
These data demonstrate the ability to ex vivo expand UCB
repopulating cells using a clinically relevant Notch ligand-based
closed culture system and suggests clinical evaluation of this ap-
proach to provide more rapid engraftment to overcome the major
disadvantage of UCB transplantation.
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CD133 HEMATOPOIETIC STEM CELLS IN CORONARY ISCHEMIA
Laughlin, Mary. Case Western Reserve University, Cleveland, OH.
Current stent and bypass therapies in coronary ischemia are
limited by problems with restenosis and microvessel disease and
innovative strategies are needed. CD133 hematopoietic stem cells
(HSC) are a focus of intensive research in attempt to augment
therapeutic neovasculogenesis in response to vascular ischemia.
Bone marrow or mobilized peripheral blood from adults has been
primarily used as a stem cell source in these laboratory studies and
early clinical trials. These studies have involved heterogenous cell
populations infused and it is unclear what speciﬁc cell populations
home to sites of ischemia and mediate neoangiogenesis. This
proposal outlines laboratory and clinical phase II studies incorpo-
rating a speciﬁed CD133 HSC cell dose administered via intra-
coronary injection for patients with chronic ischemia. The hypoth-
eses underlying our work are that CD133 HSC, rather than
mature terminally differentiated endothelial cells, are the critical
cell population that home to sites of vascular injury in response to
inﬂammatory signals and mediate new vessel formation, primarily
via stromal cells and endothelial cells present in the ischemic
vascular bed. This presentation will include a brief summary of our
ongoing studies focused on determination of vasculogenic function
and immunogenicity of marrow-derived enriched AC133HSC vs
non-selected mononuclear cells, including in vivo functional read-
outs with Doppler ﬂow measurements and histologic studies after
human cell infusions in a NOD.SCID hind-limb ischemia study
model. We are testing puriﬁed CD133 HSC cell populations in
this model including in vivo tracking to determine whether infused
human cell populations integrate and function in new vessel for-
mation, and whether infused cell populations persist over time.
This presentation will include preliminary data from our ongoing
Phase I clinical trial under FDA IND that demonstrates intracoro-
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